Viewing nowActa Zone Tablets (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
IQURE Co., Ltd.

MFDS item code 201601149 · Approved 2016.02.29 · Insurance code 674400650
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with Type 2 diabetes. It supports dietary and exercise therapies and can also be administered as monotherapy. If the patient does not respond to other oral hypoglycemic agents, it can be combined with sulfonylureas, metformin, or insulin. Additionally, it is important for patients to engage in nutritional counseling, weight loss, and regular exercise therapy. These treatment methods can help maintain drug efficacy as well as initial treatment. This medication is used for blood sugar improvement and diabetes management.
Administer this medicine orally once daily, with or without food. Diabetes management should be individualized. Ideally, response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period (at least 3 months) to evaluate changes in glycated hemoglobin, unless glycemic control worsens in a patient with diabetes. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose does not provide sufficient effect, the dose may be increased to a maximum of 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, at an initial dose of 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, at an initial dose of 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be continued when combination therapy with this medicine is initiated. However, in patients receiving this medicine with insulin who develop symptoms of hypoglycemia or whose plasma glucose concentration falls to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Further dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Patients with Renal Impairment under General Precautions). Do not initiate treatment with this medicine if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT ≥ 2.5 times the upper limit of normal) at the time treatment is started (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment and periodically thereafter. There are no data on administration of this medicine in combination with another thiazolidinedione.
Use is not recommended in children under 18 years of age because there is no experience with its use.
This medication is used for the treatment of Type 2 diabetes and helps control blood sugar levels by improving insulin sensitivity. Careful monitoring is advised for patients with heart failure, as symptoms may worsen. It should not be administered to patients with heart failure or a history of heart failure. During treatment, signs of heart failure such as changes in weight, shortness of breath, and edema should be closely observed; if these symptoms occur, the patient should consult a doctor immediately. Furthermore, this medication can cause fluid retention, which may exacerbate heart failure, so patients with edema should exercise particular caution. This medication should not be used in patients with active bladder cancer or a history of bladder cancer; any symptoms of hematuria or urinary disturbances during treatment should be reported to healthcare professionals immediately. It is also not safe for patients with compromised liver function or severe renal impairment to take this medication. Women who are pregnant or may become pregnant should not take this medication, and premenopausal women should use appropriate contraceptive measures, as this medication may enhance ovulation. There is an increased risk of hypoglycemia when this medication is combined with other diabetes medications, so dosage adjustments may be necessary. Regular blood sugar and liver function tests are important during treatment, and if abnormal symptoms occur, immediate consultation with a doctor is crucial. In cases of overdose, no specific symptoms may be present, but appropriate treatment should be provided based on symptoms. This medication has not been proven safe or effective for children, and caution should be used when administering it to the elderly. Finally, this medication should be stored in its original container and kept out of reach of children.
Congestive heart failure, excessive and rapid weight changes, dyspnea, edema, fluid retention, inadequate blood sugar control, upper respiratory infections, headache, sinusitis, myalgia, pharyngitis, abdominal bloating, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, hospitalization due to exacerbation of congestive heart failure, emergency room visit due to congestive heart failure, progression of congestive heart failure, liver failure, diabetic macular edema accompanied by visual impairment, elevated serum ALT levels, decreased hemoglobin, decreased hematocrit, increased serum creatinine, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, indigestion, nausea, dyspnea, itching, chest discomfort, tremors, chills, gastrointestinal disorders, abdominal pain, epigastric discomfort, numbness, muscle stiffness, discomfort in the head, elevated liver enzymes, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, anxiety, insomnia, drowsiness, herpes simplex, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure, fracture
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container protected from light and air, and should not be kept in places with high humidity. The optimal storage temperature is between 15 degrees and 30 degrees Celsius, ideally around 25 degrees Celsius.
White round tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
IQURE Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.